环磷酸腺苷信号、MYC与缺氧诱导因子1α交互调控B细胞淋巴瘤血管生成
研究探讨弥漫大B细胞淋巴瘤(DLBCL)中MYC与血管生成的关系,发现MYC表达与VEGF表达及血管生成正相关,且不依赖双表达状态或细胞起源分型。在常氧下cAMP抑制MYC表达、VEGFA分泌和血管生成,在缺氧下cAMP转而抑制缺氧诱导因子1α。Pde4b敲除小鼠显示cAMP/PDE4轴可直接靶向淋巴瘤微环境发挥抗血管生成作用。
要点
- 原发DLBCL活检中MYC表达与VEGF表达及血管生成正相关,不依赖双表达状态或细胞起源分型。
- 常氧下cAMP抑制MYC表达、VEGFA分泌和血管生成,缺氧下cAMP转而抑制缺氧诱导因子1α。
- Pde4b敲除小鼠显示cAMP/PDE4轴可直接靶向淋巴瘤微环境发挥额外抗血管生成作用。
核心结论
- MYC可能直接参与DLBCL血管生成,调节cAMP水平(可通过临床级PDE4抑制剂实现)在DLBCL中具有细胞和非细胞自主的抗血管生成活性。
研究设计与样本
- 研究使用原发DLBCL活检、DLBCL细胞系、患者来源异种移植模型及Pde4b敲除小鼠进行实验。
主要发现
- 原发DLBCL活检中MYC表达与VEGF表达及血管生成正相关,不依赖双表达状态或细胞起源分型。
- MYC促进VEGFA表达,该相关性在成熟B细胞肿瘤大型数据集中得到验证。
- 常氧下cAMP抑制DLBCL中MYC表达、VEGFA分泌和血管生成。
- 缺氧下cAMP转而抑制缺氧诱导因子1α。
- Pde4b敲除小鼠显示cAMP/PDE4轴通过直接靶向淋巴瘤微环境发挥额外抗血管生成作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Angiogenesis and MYC expression associate with poor outcome in diffuse large B-cell lymphoma (DLBCL). MYC promotes neo-vasculature development but whether its deregulation in DLBCL contributes to angiogenesis is unclear. Examination of this relationship may uncover novel pathogenic regulatory circuitry as well as anti-angiogenic strategies in DLBCL. Here, we show that MYC expression positively correlates with vascular endothelial growth factor (VEGF) expression and angiogenesis in primary DLBCL biopsies, independently of dual expressor status or cell-of-origin classification. We found that MYC promotes VEGFA expression, a correlation that was validated in large datasets of mature B-cell tumours. Using DLBCL cell lines and patient-derived xenograft models, we identified the second messenger cyclic-AMP (cAMP) as a potent suppressor of MYC expression, VEGFA secretion and angiogenesis in DLBCL in normoxia. In hypoxia, cAMP switched targets and suppressed hypoxia-inducible factor 1α, a master regulator of VEGFA/angiogenesis in low oxygen environments. Lastly, we used the phosphodiesterase 4b (Pde4b) knockout mouse to demonstrate that the cAMP/PDE4 axis exercises additional anti-angiogenesis by directly targeting the lymphoma microenvironment. In conclusion, MYC could play a direct role in DLBCL angiogenesis, and modulation of cAMP levels, which can be achieved with clinical grade PDE4 inhibitors, has cell and non-cell autonomous anti-angiogenic activity in DLBCL.
引用
- Ethiraj P, Sasi B, Holder KN, et al. Cyclic-AMP signalling, MYC and hypoxia-inducible factor 1α intersect to regulate angiogenesis in B-cell lymphoma. Br J Haematol. 2022. PMID: 35411936. doi:10.1111/bjh.18196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。